To investigate the effects of thalidomide on the radiosensitivity of human esophageal cancer cells (TE1 cells) and the potential mechanism underlying these effects. The effects of thalidomide on proliferation of TE1 cells were determined by Methyl thiazolyl tetrazolium assay. The multitarget click model was used to delineate the survival curve using a colony-forming assay, and the radiosensitivity was determined after TE1 cells were treated by thalidomide and/or X-ray radiation. The cell cycle was detected using flow cytometry. Our results are as follows: thalidomide alone suppressed the proliferation of TE1 cells in a dose- and time-dependent manner. The suppressive effects were enhanced by prolonged duration or elevated concentration of thalidomide. However, thalidomide did not affect the cell cycle of TE1 cells. The expression of vascular endothelial growth factor (VEGF) mRNA and protein was suppressed after treatment with thalidomide alone in a dose-dependent manner. Synergistic suppressive effects on VEGF expression were observed after administration of thalidomide and X-ray exposure. In conclusion, thalidomide was able to enhance the radiosensitivity of TE1 cells in vitro, which could be closely related to its suppressive effects on the expression of VEGF in TE1 cells, but had no obvious effects on the cell cycle.
Get full access to this article
View all access options for this article.
References
1.
ParkinDM, BrayF, FerlayJet al.Global cancer statistics, 2002. CA Cancer J Clin, 2005; 55:74.
2.
YangL, LiLD, ChenYD. Cancer incidence and mortality estimates and prediction for year 2000 and 2005 in China. Chin J Health Stat, 2005; 22:219.
3.
MarietteC, PiessenG, TribouletJP. Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol, 2007; 8:545.
4.
DelcambreC, JacobJH, PottierDet al.Localized squamous-cell cancer of the esophagus: Retrospective analysis of three treatment schedules. Radiother Oncol, 2001; 59:195.
5.
ShiXH, YaoW, LiuT. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol, 1999; 51:21.
6.
ZhaoKL, ShiXH, JiangGLet al.Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: A phase III randomized study. Int J Radiat Oncol Biol Phys, 2005; 62:1014.
7.
CooperJS, GuoMD, HerskovicAet al.Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA, 1999; 281:1623.
8.
MinskyBD, PajakTF, GinsbergRJet al.INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol, 2002; 20:1167.
9.
StahlM, StuschkeM, LehmannNet al.Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol, 2005; 23:2310.
10.
XiaoZF, YangZY, MiaoYJet al.Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: Report of 549 cases. Int J Radiat Oncol Biol Phys, 2005; 62:82.
11.
SolbergTD, NearmanJ, MullinsJet al.Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys, 2008; 72:918.
12.
KerbelRS, Viloria-PetitA, OkadaFet al.Establishing a link between oncogenes and tumor angiogenesis. Mol Med, 1998; 4:286.
13.
FerraraN. Molecular and biological properties of vascular endothelial growth factor. J Mol Med, 1999; 77:527.
14.
ByrneAM, Bouchier-HayesDJ, HarmeyJH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF)J Cell Mol Med, 2005; 9:777.
15.
CarmelietP, CollenD. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci, 2000; 902:249.
16.
FolkmanJ. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995; 1:27.
17.
DingMX, LinXQ, FuXYet al.Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma. World J Gastroenterol, 2006; 12:4582.
18.
MobiusC, FreireJ, BeckerIet al.VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg, 2007; 31:1768.
19.
HanU, CanOI, HanSet al.Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma?Dis Esophagus, 2007; 20:379.
20.
ChoiJY, JangKT, ShimYMet al.Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: Comparison with positron emission tomography. Ann Surg Oncol, 2006; 13:1054.
21.
NoguchiT, TakenoS, ShibataTet al.VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol Rep, 2002; 9:995.
22.
MatsumotoM, NatsugoeS, OkumuraHet al.Overexpression of vascular endothelial growth factor-C correlates with lymph node micrometastasis in submucosal esophageal cancer. J Gastrointest Surg, 2006; 10:1016.
23.
RadesD, GolkeH, SchildSEet al.Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy. Strahlenther Onkol, 2008; 184:416.
24.
Langeland MarthinsenAB, Dybdahl WanderasA, LundgrenSet al.Effects of growth factors on growth and radiation sensitivity of the human breast cancer cell line T-47D. Oncol Rep, 2002; 9:397.
25.
HovingaKE, StalpersLJ, van BreeCet al.Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines—a clue to radioresistance?J Neurooncol, 2005; 74:99.
AmatoRJ. Thalidomide: An antineoplastic agent. Curr Oncol Rep, 2002; 4:56.
28.
YataK, OtsukiT, KurebayashiJet al.Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells. Int J Oncol, 2003; 22:165.
29.
TeoSK. Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J, 2005; 7:E14.
JagannathS. Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma, 2007; 7,suppl5:S207.
32.
VaishampayanUN, HeilbrunLK, MarsackCet al.Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anticancer Drugs, 2007; 18:1221.
33.
PujolJL, BretonJL, GervaisRet al.Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: An intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol, 2007; 25:3945.
34.
Aragon-ChingJB, DahutWL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol, 2009; 2:161.
35.
KraemerA, HauserS, KimYet al.Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. Ger Med Sci, 2009; 7:Doc04.
36.
KozinSV, BoucherY, HicklinDJet al.Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res, 2001; 61:39.
37.
ZipsD, KrauseM, HesselFet al.Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res, 2003; 23:3869.
38.
McDonnellCO, HoldenG, SheridanMEet al.Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model. J Surg Res, 2004; 116:19.
39.
NingS, LairdD, CherringtonJMet al.The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res, 2002; 157:45.
40.
GrecoO, MarplesB, DachsGUet al.Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther, 2002; 9:1403.
41.
GorskiDH, BeckettMA, JaskowiakNTet al.Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res, 1999; 59:3374.
42.
AnsiauxR, BaudeletC, JordanBFet al.Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res, 2005; 11:743.
43.
EpperlyMW, GreenbergerEE, FranicolaDet al.Thalidomide radiosensitization of normal murine hematopoietic but not squamous cell carcinoma or multiple myeloma tumor cell lines. In Vivo, 2006; 20:333.
44.
MarriottJB, ClarkeIA, CzajkaAet al.A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res, 2003; 63:593.
45.
NgSS, GutschowM, WeissMet al.Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res, 2003; 63:3189.
46.
HideshimaT, ChauhanD, ShimaYet al.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000; 96:2943.
47.
HuangSM, HarariPM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res, 2000; 6:2166.
